Lung Cancer (Diagnosis)NCT07853443
Symptoms, Physical Function, and Recovery in Patients Receiving Lung Cancer Treatment Before Surgery
An observational study of Lung Cancer (Diagnosis) and Patient-Reported Symptom Burden, run by Aerospace Center Hospital.
Trial summary
This study will examine how symptoms and physical abilities change during lung cancer treatment given before planned surgery, and how these changes relate to recovery after surgery. Treatment given before surgery is called neoadjuvant therapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer (Diagnosis), Patient-Reported Symptom Burden, Physical Function
- What is being tested?
- Longitudinal Assessment of Symptoms, Physical Function, and Postoperative Recovery
- How many people
- 360 participants
- Where
- No sites listed yet
- Study dates
- 10 Nov 2026to 10 May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Adults aged 18 years or older with confirmed lung cancer who are scheduled to receive neoadjuvant systemic therapy followed by lung resection at Aerospace Center Hospital, Beijing, China, will be consecutively recruited before treatment begins. Treatment regimens will be selected by the treating clinical teams and recorded for analysis. Participants will undergo repeated questionnaire assessments during treatment, before surgery, and during postoperative recovery. Participants whose surgery is delayed or cancelled will remain in the cohort, with treatment changes and reasons for not proceeding to surgery documented. Postoperative outcomes will be evaluated only among participants who undergo lung resection.
Who may be able to join
- Age 18 years or older.
- Histologically or cytologically confirmed lung cancer.
- Planned neoadjuvant systemic therapy followed by lung resection, as determined by the treating multidisciplinary team.
- Enrollment and baseline questionnaire assessment before the first dose of the planned neoadjuvant treatment course.
- Able to understand and answer the study questionnaires in Chinese, independently or with standardized assistance from research staff.
- Willing to participate in assessments during treatment, before surgery, and during postoperative follow-up.
- Provides written informed consent.
Who cannot join
- The current neoadjuvant treatment course has already started before enrollment and baseline assessment.
- Cognitive impairment or another condition that prevents informed consent or reliable self-reported questionnaire responses despite assistance.
About this study
Official title: Symptom Burden, Functional Changes, and Postoperative Recovery in Patients With Lung Cancer Receiving Neoadjuvant Therapy: A Prospective Longitudinal Cohort Study
This study will examine how symptoms and physical abilities change during lung cancer treatment given before planned surgery, and how these changes relate to recovery after surgery. Treatment given before surgery is called neoadjuvant therapy.
The main questions are:
Read more
- How do symptoms and the ability to perform everyday activities change during treatment and before surgery?
- Are symptoms and reduced physical function before surgery associated with lung complications or slower recovery afterward?
- Can patient-reported information add useful information to routine preoperative assessment?
Participants will complete questionnaires before starting neoadjuvant therapy, during treatment, before surgery, and during recovery after surgery. The questionnaires will assess symptoms such as fatigue, breathlessness, and pain, along with physical abilities and well-being.
Researchers will also collect information from medical records about cancer treatment, lung function, anesthesia, surgery, pain management, and postoperative complications. Changes to the planned treatment pathway, including delays or cancellation of surgery, will be recorded.
This is an observational study. Cancer treatment, surgery, and anesthesia will be determined by the treating clinical teams, not assigned by the research team. The findings may help identify patients who need additional assessment and support before and after lung surgery.
- Being tested
- Longitudinal Assessment of Symptoms, Physical Function, and Postoperative Recovery
- Medical subject headings
- Lung Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Longitudinal Assessment of Symptoms, Physical Function, and Postoperative RecoveryOther
Participants will complete standardized patient-reported questionnaires before starting neoadjuvant therapy, during treatment, at preoperative assessment, and during postoperative recovery. Assessments will track symptom burden, physical function, and recovery over time. Each questionnaire will be administered using its specified recall period. Clinical records will provide information on treatment regimens, documented adverse events, lung function, surgery, anesthesia, analgesia, and postoperative complications. Treatment delays, changes, and reasons for not proceeding to surgery will also be recorded. These assessments are conducted for observational research only. Neoadjuvant treatment and perioperative care are determined by the treating clinical teams and are not assigned by the study.
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Postoperative Pulmonary Complications Following Lung Resection
Measured: Within 7 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2026
- Study start10 Nov 2026 (estimated)
- Primary completion10 Apr 2027 (estimated)
- Study completion10 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer (Diagnosis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 360 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aerospace Center Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07853443
- Sponsor's protocol ID
- THOR-NEO-2026-003
- Status last verified
- Sep 2026
- First submitted
- 26 Sep 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Symptom Burden, Functional Changes, and Postoperative Recovery in Patients With Lung Cancer Receiving Neoadjuvant Therapy: A Prospective Longitudinal Cohort Study
- ClinicalTrials.gov ID
- NCT07853443
- Acronym / sponsor ID
- THOR-NEO-2026-003
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 360 participants (estimated)
- Lead sponsor
- Aerospace Center HospitalUniversity, hospital or other
- Study start
- 10 Nov 2026 (estimated)
- Primary completion
- 10 Apr 2027 (estimated)
- Study completion
- 10 May 2027 (estimated)
- First posted
- 1 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will examine how symptoms and physical abilities change during lung cancer treatment given before planned surgery, and how these changes relate to recovery after surgery. Treatment given before surgery is called neoadjuvant therapy.
The main questions are:
- How do symptoms and the ability to perform everyday activities change during treatment and before surgery?
- Are symptoms and reduced physical function before surgery associated with lung complications or slower recovery afterward?
- Can patient-reported information add useful information to routine preoperative assessment?
Participants will complete questionnaires before starting neoadjuvant therapy, during treatment, before surgery, and during recovery after surgery. The questionnaires will assess symptoms such as fatigue, breathlessness, and pain, along with physical abilities and well-being.
Researchers will also collect information from medical records about cancer treatment, lung function, anesthesia, surgery, pain management, and postoperative complications. Changes to the planned treatment pathway, including delays or cancellation of surgery, will be recorded.
This is an observational study. Cancer treatment, surgery, and anesthesia will be determined by the treating clinical teams, not assigned by the research team. The findings may help identify patients who need additional assessment and support before and after lung surgery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adults aged 18 years or older with confirmed lung cancer who are scheduled to receive neoadjuvant systemic therapy followed by lung resection at Aerospace Center Hospital, Beijing, China, will be consecutively recruited before treatment begins. Treatment regimens will be selected by the treating clinical teams and recorded for analysis. Participants will undergo repeated questionnaire assessments during treatment, before surgery, and during postoperative recovery. Participants whose surgery is delayed or cancelled will remain in the cohort, with treatment changes and reasons for not proceeding to surgery documented. Postoperative outcomes will be evaluated only among participants who undergo lung resection.
Key inclusion criteria (7 listed)
- Age 18 years or older.
- Histologically or cytologically confirmed lung cancer.
- Planned neoadjuvant systemic therapy followed by lung resection, as determined by the treating multidisciplinary team.
- Enrollment and baseline questionnaire assessment before the first dose of the planned neoadjuvant treatment course.
- Able to understand and answer the study questionnaires in Chinese, independently or with standardized assistance from research staff.
Key exclusion criteria (2 listed)
- The current neoadjuvant treatment course has already started before enrollment and baseline assessment.
- Cognitive impairment or another condition that prevents informed consent or reliable self-reported questionnaire responses despite assistance.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Longitudinal Assessment of Symptoms, Physical Function, and Postoperative RecoveryParticipants will complete standardized patient-reported questionnaires before starting neoadjuvant therapy, during treatment, at preoperative assessment, and during postoperative recovery. Assessments will track symptom burden, physical function, and recovery over time. Each questionnaire will be administered using its specified recall period. Clinical records will provide information on treatment regimens, documented adverse events, lung function, surgery, anesthesia, analgesia, and postoperative complications. Treatment delays, changes, and reasons for not proceeding to surgery will also be recorded. These assessments are conducted for observational research only. Neoadjuvant treatment and perioperative care are determined by the treating clinical teams and are not assigned by the study. | Other | – |
Primary outcome
Incidence of Postoperative Pulmonary Complications Following Lung Resection
Time frame: Within 7 days after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2026.
Related trials for Lung Cancer (Diagnosis)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer (Diagnosis) and Patient-Reported Symptom Burden, run by Aerospace Center Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Postoperative Pulmonary Complications Following Lung Resection (time frame: Within 7 days after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.